Table 5.14Incremental costs and effectiveness by treatment strategy for Hodgkin lymphoma patients (baseline risk of neutropenic sepsis of one course of chemotherapy: 20.27%)

StrategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£) versus baseline (QALYs)ICER (£) incremental (QALYs)
Nothing/Placebo£235.8-1.2*10-3——ComparatorComparator
Secondary prophylaxis with G(M)-CSF£1,608.8-1.1*10-3£1,372.07.5*10-5£18.2 million£18.2 million
Primary prophylaxis with G(M)-CSF£11,921.8-9.3*10-4£11,686.02.5*10-4£47.2 million£59.9 million

From: 5, Reducing the risk of septic complications of anticancer treatment

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.